The most common primary end-point of the trial on treatment of traumatic spinal cord injury
(SCI) is the degree of impairment. The American Spinal Injury Association (ASIA) Standards …

Acute traumatic spinal cord injury (SCI) affects 12 000 to 15 000 people in North America
each year. The functional consequences of an acute SCI are variable; therefore, the initial …

Olfactory ensheathing cells show promise in preclinical animal models as a cell
transplantation therapy for repair of the injured spinal cord. This is a report of a clinical trial of …

Electrical neuromodulation of spinal networks improves the control of movement of the
paralyzed limbs after spinal cord injury (SCI). However, the potential of noninvasive spinal …

Context: Spinal cord injury (SCI) can cause irreversible damage to neural tissues. However,
there is currently no effective treatment for SCI. The therapeutic potential of adipose-derived …

Chondroitinase ABC is a promising preclinical therapy that promotes functional
neuroplasticity after CNS injury by degrading extracellular matrix inhibitors. Efficient delivery …

Study design: Retrospective, longitudinal analysis of motor recovery data from individuals
with cervical (C4–C7) sensorimotor complete spinal cord injury (SCI) according to the …

Study design: This is a clinical trial (phase 1). Objectives: The objective of this study was to
asses the safety and feasibility of bone marrow mesenchymal stem cell (MSC) and Schwann …

Objective. The aim of the present study was to assess gait speeds that distinguished
between levels of functional ambulation in subjects with a spinal cord injury. Methods. The …

Study design: Retrospective, longitudinal analysis of sensory, motor and functional
outcomes from individuals with thoracic (T2–T12) sensorimotor complete spinal cord injury …